UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation

Sibirskiĭ onkologicheskiĭ zhurnal, 2022-11, Vol.21 (5), p.135-141

2022

Volltextzugriff (PDF)

ROR1 and BMI-1 proteins as potential predictors of the effectiveness of hormone therapy in luminal breast cancer

Sibirskiĭ onkologicheskiĭ zhurnal, 2022-06, Vol.21 (3), p.135-142

2022

Volltextzugriff (PDF)

Exome Sequencing: the Search for Mutations Associated with Hereditary Breast and Ovarian Cancers in the Tuvan Ethnic Group (A Pilot Study)

Bulletin of experimental biology and medicine, 2024-04, Vol.176 (6), p.801-805

2024

Volltextzugriff (PDF)

Short-term outcomes of neoadjuvant chemotherapy in colorectal cancer patients with isolated liver metastasis

Sibirskiĭ onkologicheskiĭ zhurnal, 2023-01, Vol.21 (6), p.17-24

2023

Volltextzugriff (PDF)

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Contributes to Tamoxifen Resistance in Estrogen-Positive Breast Cancer Patients

Molecular biology (New York), 2021, Vol.55 (1), p.102-108

2021

Volltextzugriff (PDF)

New mutation of the TP53 gene associated with the hereditary breast cancer in a young Tuvinian woman

Sibirskiĭ onkologicheskiĭ zhurnal, 2022-01, Vol.20 (6), p.164-170

2022

Volltextzugriff (PDF)

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Contributes to Tamoxifen Resistance in Estrogen-Positive Breast Cancer Patients

Molekuliarnaia biologiia, 2021-01, Vol.55 (1), p.118

2021

Volltextzugriff (PDF)

Mesenchymal Subtype of Triple-Negative Breast Cancer: A Review of Specific Features

International journal of biomedicine, 2023-03, Vol.13 (1), p.14-19

2023

Volltextzugriff (PDF)

ROLE OF CYCLIN D1 IN THE MECHANISMS OF TAMOXIFEN RESISTANCE

Sibirskiĭ onkologicheskiĭ zhurnal, 2020-09, Vol.19 (4), p.138-145

2020

Volltextzugriff (PDF)

Multimodal therapy for metastatic colorectal cancer: a case of complete clinical and radiological response of liver metastases

Sibirskiĭ onkologicheskiĭ zhurnal, 2024-03, Vol.23 (1), p.162-169

2024

Volltextzugriff (PDF)

Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis

DNA and cell biology, 2012-03, Vol.31 (3), p.306

2012

Volltextzugriff (PDF)

P6

European journal of cancer supplements, 2015-11, Vol.13 (1), p.2-3

2015

Volltextzugriff (PDF)

24P TGF-βRI contributes to tamoxifen response in luminal B breast cancer with HER2-negative phenotype

Annals of oncology, 2021-10, Vol.32, p.S1353

2021

Volltextzugriff (PDF)

46P ERα heterogeneous expression and the TGF-βRI status in the tumour predicted tamoxifen resistance

Annals of oncology, 2021-03, Vol.32, p.S18-S19

2021

Volltextzugriff (PDF)

Predictive Significance of Vascular Endothelial Growth Factor receptor VEGF-2 in triple-negative breast cancer patients

Sibirskiĭ onkologicheskiĭ zhurnal, 2016-11, Vol.15 (5), p.9-17

2016

Volltextzugriff (PDF)

23P Different profile of receptor tyrosine kinases expression in breast cancer molecular subtypes

Annals of oncology, 2020-10, Vol.31, p.S1224-S1224

2020

Volltextzugriff (PDF)

94P Coexpression of PI3K/Akt signaling components and breast stem cells markers: Potential contributions in resistance to tamoxifen treatment

Annals of oncology, 2020-09, Vol.31, p.S278-S278

2020

Volltextzugriff (PDF)

ROLE OF TRANSFORMING GROWTH FACTOR RECEPTOR B I TYPE (TGF-BRI) IN THE PROGRESSION OF THE LUMINAL BREAST CANCER SUBTYPE

Sibirskiĭ onkologicheskiĭ zhurnal, 2017-06, Vol.16 (2), p.27-35

2017

Volltextzugriff (PDF)

ANALYSIS OF ASSOCIATIONS OF VEGF-A GENE POLYMORPHISM AT POSITIONS 2578A/C AND +936C/T WITH DIFFERENT RECEPTOR STATUS IN BREAST CANCER PATIENTS

Sibirskiĭ onkologicheskiĭ zhurnal, 2016-02 (1), p.32-37

2016

Volltextzugriff (PDF)

ROLE OF MORPHOLOGICAL AND GENETIC STRUCTURAL CHARACTERISTICS OF ESTROGEN RECEPTOR ALPHA IN THE DEVELOPMENT OF RESISTANCE TO ENDOCRINOTHERAPY WITH TAMOXIFEN IN PATIENTS WITH LUMINAL BREAST CANCER

Sibirskiĭ onkologicheskiĭ zhurnal, 2016-02 (3), p.39-44

2016

Volltextzugriff (PDF)

Chitinase-like proteins as candidate markers for tamoxifen responsiveness

European journal of cancer (1990), 2020-10, Vol.138, p.S41-S42

2020

Volltextzugriff (PDF)

P190 Molecular breast cancer subtypes: relationship with clinicopathological characteristics, efficacy of neoadjuvant chemotherapy and survival

Breast (Edinburgh), 2011, Vol.20, p.S41-S41

2011

Volltextzugriff (PDF)

RELATIONSHIP OF THE IMMUNOLOGICAL PARAMETRES WITH NEOADJUVANT CHEMOTHERAPY EFFECTIVENESS IN BREAST CANCER PATIENTS

Sibirskiĭ onkologicheskiĭ zhurnal, 2016-02 (2), p.50-57

2016

Volltextzugriff (PDF)

FEATURES OF EXPRESSION OF TRANSFORMING GROWTH FACTOR BETA IN ESTROGEN-POSITIVE BREAST CANCER

Cardiometry, 2022-11 (24), p.61-62

2022

Volltextzugriff (PDF)

MOLECULAR PROFILE OF METASTATIC COLON CANCER

Cardiometry, 2023-11 (29), p.10-11

2023

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(32)
Tagungsberichte
(1)

Sprache

Englisch
(28)
Russisch
(13)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation

ROR1 and BMI-1 proteins as potential predictors of the effectiveness of hormone therapy in luminal breast cancer

Exome Sequencing: the Search for Mutations Associated with Hereditary Breast and Ovarian Cancers in the Tuvan Ethnic Group (A Pilot Study)

Short-term outcomes of neoadjuvant chemotherapy in colorectal cancer patients with isolated liver metastasis

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Contributes to Tamoxifen Resistance in Estrogen-Positive Breast Cancer Patients

New mutation of the TP53 gene associated with the hereditary breast cancer in a young Tuvinian woman

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Contributes to Tamoxifen Resistance in Estrogen-Positive Breast Cancer Patients

Mesenchymal Subtype of Triple-Negative Breast Cancer: A Review of Specific Features

ROLE OF CYCLIN D1 IN THE MECHANISMS OF TAMOXIFEN RESISTANCE

Multimodal therapy for metastatic colorectal cancer: a case of complete clinical and radiological response of liver metastases

Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis

P6

24P TGF-βRI contributes to tamoxifen response in luminal B breast cancer with HER2-negative phenotype

46P ERα heterogeneous expression and the TGF-βRI status in the tumour predicted tamoxifen resistance

Predictive Significance of Vascular Endothelial Growth Factor receptor VEGF-2 in triple-negative breast cancer patients

23P Different profile of receptor tyrosine kinases expression in breast cancer molecular subtypes

94P Coexpression of PI3K/Akt signaling components and breast stem cells markers: Potential contributions in resistance to tamoxifen treatment

ROLE OF TRANSFORMING GROWTH FACTOR RECEPTOR B I TYPE (TGF-BRI) IN THE PROGRESSION OF THE LUMINAL BREAST CANCER SUBTYPE

ANALYSIS OF ASSOCIATIONS OF VEGF-A GENE POLYMORPHISM AT POSITIONS 2578A/C AND +936C/T WITH DIFFERENT RECEPTOR STATUS IN BREAST CANCER PATIENTS

ROLE OF MORPHOLOGICAL AND GENETIC STRUCTURAL CHARACTERISTICS OF ESTROGEN RECEPTOR ALPHA IN THE DEVELOPMENT OF RESISTANCE TO ENDOCRINOTHERAPY WITH TAMOXIFEN IN PATIENTS WITH LUMINAL BREAST CANCER

Chitinase-like proteins as candidate markers for tamoxifen responsiveness

P190 Molecular breast cancer subtypes: relationship with clinicopathological characteristics, efficacy of neoadjuvant chemotherapy and survival

RELATIONSHIP OF THE IMMUNOLOGICAL PARAMETRES WITH NEOADJUVANT CHEMOTHERAPY EFFECTIVENESS IN BREAST CANCER PATIENTS

FEATURES OF EXPRESSION OF TRANSFORMING GROWTH FACTOR BETA IN ESTROGEN-POSITIVE BREAST CANCER

MOLECULAR PROFILE OF METASTATIC COLON CANCER

Suchergebnisse filtern